background
rapid
specif
molecular
test
identif
recent
identifi
pandem
influenza
viru
well
rapid
molecular
test
identifi
antivir
resist
strain
urgent
need
object
evalu
perform
two
novel
revers
transcriptas
polymeras
chain
reaction
rtpcr
target
specif
hemagglutinin
neuraminidas
pandem
influenza
viru
combin
conserv
matrix
pcr
addit
investig
perform
novel
discrimin
rtpcr
detect
resist
mutat
neuraminidas
gene
studi
design
clinic
perform
subtyp
specif
rtpcr
assay
evalu
analysi
throat
swap
collect
individu
meet
case
definit
novel
pandem
influenza
viru
analyt
perform
analyz
test
serial
dilut
rna
deriv
first
dutch
sequenc
cultur
confirm
case
novel
pandem
influenza
infect
specif
discrimin
capac
discrimin
assay
perform
test
wild
type
recombin
pandem
influenza
result
throat
swap
collect
april
juli
posit
least
two
three
rtpcr
neg
season
subtyp
specif
rtpcr
assay
test
posit
three
ctvalu
oseltamivir
resist
detect
conclus
present
sensit
specif
approach
detect
pandem
influenza
rapid
rtpcr
assay
detect
primari
oseltamivir
resist
mutat
incorpor
easili
clinic
virolog
algorithm
background
rapid
specif
molecular
test
identif
recent
identifi
pandem
influenza
viru
well
rapid
molecular
test
identifi
antivir
resist
strain
urgent
need
object
evalu
perform
two
novel
revers
transcriptas
polymeras
chain
reaction
rtpcr
target
specif
hemagglutinin
neuraminidas
pandem
influenza
viru
combin
conserv
matrix
pcr
addit
investig
perform
novel
discrimin
rtpcr
detect
resist
mutat
neuraminidas
gene
studi
design
clinic
perform
subtyp
specif
rtpcr
assay
evalu
analysi
throat
swap
collect
individu
meet
case
definit
novel
pandem
influenza
viru
analyt
perform
analyz
test
serial
dilut
rna
deriv
first
dutch
sequenc
cultur
confirm
case
novel
pandem
influenza
infect
specif
discrimin
capac
discrimin
assay
perform
test
wild
type
recombin
pandem
influenza
result
throat
swap
collect
april
juli
posit
least
two
three
rtpcr
neg
season
subtyp
specif
rtpcr
assay
test
posit
three
ctvalu
oseltamivir
resist
detect
conclus
present
sensit
specif
approach
detect
pandem
influenza
rapid
rtpcr
assay
detect
primari
oseltamivir
resist
mutat
incorpor
easili
clinic
virolog
algorithm
elsevi
bv
right
reserv
world
stockpil
antivir
drug
treatment
infect
patient
minim
spread
viru
first
pandem
phase
period
appropri
vaccin
pandem
influenza
strain
avail
rapid
detect
pandem
influenza
variant
distinguish
strain
circul
epidem
strain
identif
antivir
resist
variant
import
pandem
surveil
patient
manag
current
pandem
influenza
variant
natur
resist
amantadin
rimantidin
still
suscept
neuraminidas
inhibitor
nai
oseltamivir
tamiflu
zanamivir
relenza
sinc
begin
season
influenza
epidem
resist
influenza
virus
antivir
drug
oseltamivir
caus
concern
circul
virus
year
found
oseltamivir
resist
earli
data
southern
hemispher
suggest
oseltamivir
resist
epidem
virus
found
resist
histidin
tyrosin
substitut
viral
neuraminidas
posit
residu
gene
resist
mutat
found
virus
isol
influenza
infect
patient
treat
oseltamivir
consequ
massiv
use
nai
pandem
appear
influenza
virus
resist
drug
expect
gold
standard
antivir
resist
screen
phenotyp
resist
assay
time
consum
would
includ
viral
cultur
pandem
strain
date
nai
resist
pattern
pandem
influenza
viru
unknown
howev
potenti
resist
pattern
may
occur
similar
way
sinc
structur
comparison
neuraminidas
epidem
pandem
influenza
show
great
similar
activ
site
enzym
singl
nucleotid
mutat
cytosin
thymin
posit
pandem
neuraminidas
gene
result
histidin
tyrosin
substitut
posit
pyrosequenc
method
detect
singl
nucleotid
polymorph
snp
becom
well
accept
method
sensit
screen
snp
resist
mutat
howev
result
extens
wash
procedur
revers
transcriptas
polymeras
chain
reaction
rtpcr
gener
amplicon
techniqu
may
lead
fals
posit
result
rtpcr
use
snp
analysi
well
design
primer
probe
discrimin
wild
type
mutant
sequenc
excel
discrimin
properti
achiev
incorpor
lockednucl
acid
lna
base
probe
increas
melt
temperatur
thu
allow
probe
shorter
increas
discrimin
capac
develop
evalu
perform
novel
rtpcr
assay
target
hemagglutinin
neuraminidas
gene
pandem
influenza
viru
discrimin
assay
detect
oseltamivir
resist
mutat
neuraminidas
laboratori
cultur
influenza
viru
v
propag
madindarbi
canin
kidney
mdck
cell
titer
tcid
ml
serial
dilut
posit
control
sampl
convers
rtpcr
threshold
cycl
ct
valu
semiquantit
viral
particl
count
dilut
electron
microscop
count
influenza
viru
stock
advanc
bioscienc
columbia
usa
run
parallel
obtain
pandem
influenza
neuraminidas
target
substitut
neuraminidas
influenza
viru
genbank
access
number
neuraminidas
gene
rescu
describ
previous
neuraminidas
gene
clone
cytosin
thymin
mutat
introduc
posit
sitedirect
mutagenesi
quickchang
stratagen
netherland
primer
sens
valid
subtyp
specif
rtpcr
assay
total
sampl
use
collect
suspect
pandem
influenza
infect
individu
accord
case
definit
suspect
novel
pandem
influenza
case
sampl
test
influenza
slightli
modifi
version
previous
describ
rtpcr
target
conserv
region
influenza
matrix
gene
neuraminidas
gene
clinic
isol
viral
load
higher
viral
particl
per
millilit
vpml
sequenc
convent
sanger
sequenc
crossreact
rtpcr
assay
check
analyz
throat
swap
test
posit
season
influenza
design
primer
probe
pandem
influenza
rtpcr
assay
refer
sequenc
hemagglutinin
ha
neuraminidas
na
deposit
ncbi
nation
center
biotechnolog
inform
access
may
align
clustalw
primer
express
softwar
appli
biosystem
nieuwerkerk
ad
ijssel
netherland
use
design
primer
probe
primer
probe
discrimin
assay
design
around
nucleotid
posit
neuraminidas
gene
five
lna
base
incorpor
probe
allow
shorter
increas
discrimin
capac
primer
probe
list
tabl
eurogentec
maastricht
netherland
evalu
primer
probe
discrimin
assay
two
plasmid
nucleic
acid
extract
l
respiratori
specimen
nucleic
acid
elut
volum
l
use
pathogen
complex
protocol
qiasymphoni
machin
qiagen
venlo
netherland
accord
instruct
manufactur
monitor
whole
process
isol
nucleic
acid
rtpcr
univers
intern
control
consist
seal
distemp
viru
pdv
prepar
ad
origin
clinic
sampl
rtthbase
ez
rtpcr
kit
appli
biosystem
nieuwerkerk
ad
ijssel
netherland
use
rtpcr
assay
differ
cycl
condit
influenza
matrix
pandem
rtpcr
follow
amplif
condit
use
ung
reaction
c
min
cdna
reaction
c
min
pcr
amplif
c
min
follow
cycl
c
c
min
matrix
rtpcr
includ
pmol
forward
pmol
revers
primer
pmol
probe
pandem
rtpcr
pmol
primer
pmol
probe
use
discrimin
assay
compromis
pmol
forward
revers
primer
pmol
probe
thermal
cycl
profil
similar
except
elong
temperatur
c
instead
c
reaction
done
total
reaction
volum
l
includ
l
nucleic
acid
amplif
detec
tion
perform
lightcycl
instrument
use
fam
nm
dragonfli
nm
filter
roch
almer
netherland
serial
dilut
rna
pandem
influenza
strain
rnasefre
water
use
determin
linear
rang
rtpcr
assay
target
hemagglutinin
neuraminidas
gene
approxim
sensit
rtpcr
assay
determin
viral
particl
per
millilit
vpml
reaction
detect
vpml
reaction
detect
assay
linear
wide
clinic
signific
rang
slope
r
r
rtpcr
respect
see
fig
analysi
throat
swap
collect
individu
suspect
infect
pandem
influenza
reveal
pandem
influenza
sampl
test
posit
least
two
three
rtpcr
assay
see
tabl
sampl
followup
sampl
total
sampl
test
posit
influenza
matrix
ctvalu
subtyp
rtpcr
assay
sampl
detect
rtpcr
high
ctvalu
indic
low
viral
load
sampl
total
pandem
viru
neg
sampl
test
crossreact
sampl
test
posit
season
influenza
viru
confirm
contain
least
one
respiratori
viru
crossreact
observ
test
sampl
assay
sensit
test
use
rna
obtain
influenza
viru
well
recombin
target
cutoff
valu
determin
approxim
vpml
ct
serial
dilut
vitro
transcrib
rna
contain
wild
type
mutant
sequenc
analyz
use
discrimin
rtpcr
assay
two
differ
label
lna
probe
use
multiplex
assay
allow
data
acquisit
fam
nm
dragonfli
nm
filter
wild
type
rna
present
fluoresc
detect
famfilt
vice
versa
mutant
rna
present
fluoresc
emiss
detect
dragonfli
filter
wild
type
mutant
fluoresc
emit
neg
control
sampl
use
check
crossreact
mixtur
wild
type
mutant
rna
mutant
viru
could
detect
reaction
total
input
vpml
addit
analyz
clinic
sampl
oseltamivir
pandem
influenza
infect
patient
wild
type
genotyp
found
see
fig
within
first
month
novel
pandem
influenza
outbreak
antivir
drug
wide
use
treatment
infect
patient
temper
viral
transmiss
current
vaccin
avail
antivir
drug
line
defens
recent
pandem
influenza
sequenc
upload
influenza
sequenc
databas
encod
variant
genbank
access
still
unclear
whether
viru
oseltamivir
resist
transmit
sinc
global
spread
oseltamivir
resist
season
influenza
viru
popul
focu
mutat
need
evalu
novel
rtpcr
assay
subtyp
pandem
influenza
viru
rtpcr
sensit
specif
incorpor
directli
exist
influenza
detect
subtyp
algorithm
valid
discrimin
assay
viru
isol
chosen
deriv
pandem
influenza
infect
patient
oseltamivir
treatment
patient
respond
well
oseltamivir
treatment
gener
therefor
assum
minor
variant
present
sampl
taken
sampl
baselin
oseltamivir
resist
mutant
could
detect
mix
viru
popul
use
discrimin
assay
see
fig
drawback
genotyp
screen
antivir
resist
mutat
rtpcr
potenti
appear
unwant
mismatch
primer
probe
region
due
antigen
drift
diagnost
purpos
discrimin
rtpcr
assay
therefor
perform
parallel
influenza
rtpcr
assay
target
conserv
region
influenza
viral
genom
conclus
subtyp
rtpcr
assay
describ
appear
sensit
specif
valid
pilot
use
discrimin
rtpcr
pandem
influenza
virus
screen
oseltamivir
suscept
within
h
time
make
use
surveil
valuabl
clinic
patient
manag
none
declar
